TSX runs higher on rate cut expectations
Director Richard Douglas recently purchased 80,000 shares of MAXCYTE, INC. (NASDAQ:MXCT) common stock, according to a Form 4 filing with the Securities and Exchange Commission. The timing is notable as InvestingPro data shows the stock has declined over 66% year-to-date and appears undervalued based on Fair Value analysis. The shares were bought in a series of transactions at prices ranging from $1.30 to $1.40, for a total value of $111,039.
Following the purchase on August 13, 2025, Douglas directly owns 230,577 shares of Maxcyte.
In other recent news, MaxCyte Inc. reported its second-quarter 2025 earnings, revealing a revenue miss. The company posted earnings per share of -$0.12, slightly below the expected -$0.10, and revenue came in at $8.5 million, falling short of the $9.63 million forecast. This represents an 11.73% miss in revenue expectations. Following these results, MaxCyte reduced its 2025 revenue guidance by $5 million, indicating a 14% impact on its business, and now expects its core business to decline approximately 5% year-over-year in 2025. In response to these developments, BTIG downgraded MaxCyte from Buy to Neutral, citing ongoing funding challenges for the company’s cell and gene therapy customers. William Blair also downgraded MaxCyte from Outperform to Market Perform, highlighting the company’s disappointing performance and reduced guidance. The revised guidance indicates a potential decline of 6%-16% in core organic revenue for the year, including an approximately 20% drop in the second half.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.